Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: A double blind randomized placebo controlled study

Digestive and Liver Disease

Volumn 32, Issue 4, 2000, Pages 335-338

  Laccetti, M ^a,b   Manes, G ^a   Uomo, G ^a   Lioniello, M ^a   Rabitti, P G ^a   Balzano, A ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Flumazenil; Hepatic encephalopathy; Liver cirrhosis

Indexed keywords

BRANCHED CHAIN AMINO ACID; FLUMAZENIL; GLUCOSE; LACTULOSE; PLACEBO; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLASGOW COMA SCALE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033932980     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1590-8658(00)80027-4     Document Type: Article

References (11)

1. Jones EA, Basile AS, Mullen KD, Gammal SH. Flumazenil: potential implications for hepatic encephalopathy. Pharmacol Therap 1990;45:331-43.
2. Baraldi M, Zeneroli ML, Ventura E. Supersensitivity of benzodiazepine receptors in hepatic encephalopathy due to fulminant hepatic failure in the rat: reversal by a benzodiazepine antagonist. Clin Sci 1984;67:167-75.
3. Basset ML, Mullen KD, Skolnik P, Jones EA. Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABA benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure. Gastroenterology 1987;93:1069-77.
4. Baraldi M, Zeneroli ML. Experimental hepatic encephalopathy: changes in the binding of gamma-aminobutyric acid. Science 1982;216:427-9.
5. Grimm G, Ferenci P, Katzenschlager R, Madl C, Schneeweiss B, Laggner AN, et al. Improvement of hepatic encephalopathy treated with flumazenil. Lancet 1988;2:1392-4.
6. Meier R, Gyr K. Treatment of hepatic encephalopathy with the benzodiazepine antagonist Flumazenil: a pilot study. Eur J Anaesthesiol 1988;2(Suppl):139-46.
7. Bansky G, Meier PJ, Riedener E, Walser H, Ziegler WH, Schmid M. Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology 1989;97:744-50.
8. Pomier-Layragues G, Giguere JF, Lavoie J, Perney P, Gagnon S, D'Amour M, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo controlled crossover trial. Hepatology 1994;19:32-7.
9. Cadramel JF, el Younsi MM, Pidoux B, Zylberberg P, Benhamou Y, Valla D, et al. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized placebo study. Eur J Gastroenterol Hepatol 1995;7:325-9.
10. Gyr K, Meier R, Häussler J, Boulétreau, Fleig WE, Gatta A, et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. Gut 1996;39:319-24.
11. Barbaro G, DiLorenzo G, Soldini M, Giancaspro G, Bellomo G, Belloni G, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: An Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998;28:374-8.